Amgen, Inc. (AMGN)
443.84
+4.51
(+1.03%)
USD |
NASDAQ |
Aug 24, 16:00
444.00
+0.16
(+0.04%)
After-Hours: 20:00
Amgen Enterprise Value : 280.82B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 280.82B |
| August 20, 2026 | 277.79B |
| August 19, 2026 | 282.45B |
| August 18, 2026 | 273.22B |
| August 17, 2026 | 270.03B |
| August 14, 2026 | 267.78B |
| August 13, 2026 | 269.20B |
| August 12, 2026 | 268.30B |
| August 11, 2026 | 267.29B |
| August 10, 2026 | 268.85B |
| August 07, 2026 | 265.47B |
| August 06, 2026 | 262.18B |
| August 05, 2026 | 263.79B |
| August 04, 2026 | 254.16B |
| August 03, 2026 | 248.13B |
| July 31, 2026 | 251.53B |
| July 30, 2026 | 252.87B |
| July 29, 2026 | 252.87B |
| July 28, 2026 | 255.82B |
| July 27, 2026 | 246.72B |
| July 24, 2026 | 246.60B |
| July 23, 2026 | 244.15B |
| July 22, 2026 | 241.20B |
| July 21, 2026 | 241.30B |
| July 20, 2026 | 240.19B |
| Date | Value |
|---|---|
| July 17, 2026 | 241.33B |
| July 16, 2026 | 244.19B |
| July 15, 2026 | 237.02B |
| July 14, 2026 | 235.36B |
| July 13, 2026 | 238.17B |
| July 10, 2026 | 239.76B |
| July 09, 2026 | 239.89B |
| July 08, 2026 | 242.25B |
| July 07, 2026 | 242.31B |
| July 06, 2026 | 241.41B |
| July 02, 2026 | 245.58B |
| July 01, 2026 | 238.65B |
| June 30, 2026 | 239.08B |
| June 29, 2026 | 239.87B |
| June 26, 2026 | 238.68B |
| June 25, 2026 | 235.70B |
| June 24, 2026 | 234.95B |
| June 23, 2026 | 232.57B |
| June 22, 2026 | 231.33B |
| June 18, 2026 | 227.49B |
| June 17, 2026 | 229.68B |
| June 16, 2026 | 233.01B |
| June 15, 2026 | 234.47B |
| June 12, 2026 | 236.99B |
| June 11, 2026 | 236.37B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 202.61B |
| Regeneron Pharmaceuticals, Inc. | 80.94B |
| AbbVie, Inc. | 532.50B |
| Biogen, Inc. | 39.09B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.375B |
| Revenue (Quarterly) | 10.07B |
| Total Expenses (Quarterly) | 7.692B |
| EPS Diluted (Quarterly) | 4.366 |
| Gross Profit Margin (Quarterly) | 72.08% |
| Profit Margin (Quarterly) | 23.59% |
| Earnings Yield | 3.63% |
| Operating Earnings Yield | 5.28% |
| Normalized Earnings Yield | 3.975 |